BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 11209089)

  • 1. Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients.
    Gazitt Y; Liu Q
    Stem Cells; 2001; 19(1):37-45. PubMed ID: 11209089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of adhesion molecules on CD34(+) cells in peripheral blood of non-hodgkin's lymphoma patients mobilized with different growth factors.
    Gazitt Y; Shaughnessy P; Liu Q
    Stem Cells; 2001; 19(2):134-43. PubMed ID: 11239168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4.
    Gazitt Y; Akay C
    Stem Cells; 2004; 22(1):65-73. PubMed ID: 14688392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of FL and SDF-1 and expression of FLT-3 and CXCR4 on CD34+ cells assessed pre and post hematopoietic stem cell mobilization in patients with hematologic malignancies and in healthy donors.
    Cecyn KZ; Schimieguel DM; Kimura EY; Yamamoto M; Oliveira JS
    Transfus Apher Sci; 2009 Jun; 40(3):159-67. PubMed ID: 19380254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High steady-state plasma levels of flt3-ligand in the peripheral blood is a good predictor for poor mobilization of CD34+ PBSC in patients undergoing high-dose chemotherapy and stem cell rescue.
    Gazitt Y; Liu Q
    J Hematother Stem Cell Res; 2000 Apr; 9(2):285-93. PubMed ID: 10813543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
    Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
    Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
    Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
    Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of matrix metalloproteinase-9 in granulocyte colony stimulation factor-induced stem cell mobilization].
    Jin FY; Qiu LG; Li QC; Meng HX; Wang YF; Yu Z; Li Q; Han JL
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(42):2966-70. PubMed ID: 17288807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F; Cavenaghi L; de Melo CM
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of stromal cell-derived factor and its receptor-CXCR4 in G-CSF-induced hematopoietic stem cell mobilization].
    Jin FY; Qiu LG; Li QC; Meng HX; Wang YF; Yu Z; Li Q; Han JL
    Zhonghua Xue Ye Xue Za Zhi; 2007 Feb; 28(2):98-102. PubMed ID: 17650669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor.
    Pelus LM; Bian H; Fukuda S; Wong D; Merzouk A; Salari H
    Exp Hematol; 2005 Mar; 33(3):295-307. PubMed ID: 15730853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients.
    Watts MJ; Ings SJ; Leverett D; MacMillan A; Devereux S; Goldstone AH; Linch DC
    Br J Cancer; 2000 Jan; 82(2):278-82. PubMed ID: 10646877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction.
    Wojakowski W; Tendera M; Michałowska A; Majka M; Kucia M; Maślankiewicz K; Wyderka R; Ochała A; Ratajczak MZ
    Circulation; 2004 Nov; 110(20):3213-20. PubMed ID: 15533859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
    Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
    J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34+ cell responsiveness to stromal cell-derived factor-1alpha underlies rate of engraftment after peripheral blood stem cell transplantation.
    Marquez-Curtis LA; Turner AR; Larratt LM; Letcher B; Lee SF; Janowska-Wieczorek A
    Transfusion; 2009 Jan; 49(1):161-9. PubMed ID: 18954402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degradation of BM SDF-1 by MMP-9: the role in G-CSF-induced hematopoietic stem/progenitor cell mobilization.
    Jin F; Zhai Q; Qiu L; Meng H; Zou D; Wang Y; Li Q; Yu Z; Han J; Li Q; Zhou B
    Bone Marrow Transplant; 2008 Nov; 42(9):581-8. PubMed ID: 18679363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
    Gazitt Y; Akay C; Thomas C
    Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
    Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
    Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.